Dermata Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

DRMA$0.76+0.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Par Value	Capital	Deficit	Equity
Balance at December 31, 2024	2,517,768	$252	$67,236,181	$(65,675,339)	$1,561,094
Stock-based compensation	-	-	37,189	-	37,189
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs	1,935,412	193	2,254,528	-	2,254,721
Issuance of Common Stock upon exercise of pre-funded warrants	977,468	98	879	-	977
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs	602,000	60	5,750,768	-	5,750,828
Net loss	-	-	-	(2,303,587)	(2,303,587)
Balance at March 31, 2025	6,032,648	$603	$75,279,545	$(67,978,926)	$7,301,222

Statements of Stockholder’s Equity

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Par Value	Capital	Deficit	Equity
Balance at December 31, 2023	261,998	$26	$59,742,870	$(53,387,878)	$6,355,018
Stock-based compensation	-	-	587,234	-	587,234
Issuance of abeyance shares	182,000	18	(18)	-	-
Net loss	-	-	-	(3,134,262)	(3,134,262)
Balance at March 31, 2024	443,998	$44	$60,330,086	$(56,522,140)	$3,807,990

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.